Royalty Pharma Files 8-K on Financial Results, Exhibits
Ticker: RPRX · Form: 8-K · Filed: Jan 8, 2024 · CIK: 1802768
| Field | Detail |
|---|---|
| Company | Royalty Pharma PLC (RPRX) |
| Form Type | 8-K |
| Filed Date | Jan 8, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: financial-results, 8-K, corporate-filing
TL;DR
**Royalty Pharma just dropped an 8-K with new financial results, time to check the numbers.**
AI Summary
Royalty Pharma plc filed an 8-K on January 8, 2024, to report on its 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits.' This filing, under SEC File Number 001-39329, indicates that the company is providing an update on its financial performance and related disclosures. For investors, this matters because it signals that new financial information is available, which could impact their valuation of the company's Class A Ordinary Shares (RPRX) traded on The Nasdaq Stock Market LLC.
Why It Matters
This filing indicates that Royalty Pharma plc has released new financial information, which is crucial for investors to assess the company's current health and future prospects. Understanding these results can directly influence investment decisions regarding RPRX shares.
Risk Assessment
Risk Level: low — This 8-K is a routine disclosure of financial information, not an announcement of a major adverse event, thus posing a low direct risk.
Analyst Insight
A smart investor would closely monitor the full content of the 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits' referenced in this 8-K to understand Royalty Pharma plc's latest performance and adjust their investment thesis for RPRX accordingly.
Key Numbers
- 001-39329 — SEC File Number (identifies Royalty Pharma plc's registration with the SEC)
- 2024-01-08 — Date of Report (indicates when the earliest event reported in the 8-K occurred)
- $0.0001 — par value per share (par value of Royalty Pharma plc's Class A Ordinary Shares)
Key Players & Entities
- Royalty Pharma plc (company) — the registrant filing the 8-K
- January 8, 2024 (date) — date of the earliest event reported and filing date
- 001-39329 (dollar_amount) — SEC File Number for Royalty Pharma plc
- RPRX (company) — trading symbol for Royalty Pharma plc's Class A Ordinary Shares
- The Nasdaq Stock Market LLC (company) — exchange where RPRX shares are registered
Forward-Looking Statements
- Analysts will review the detailed financial statements and exhibits to update their price targets for RPRX. (RPRX) — high confidence, target: 2024-01-31
- The market will react to the 'Results of Operations and Financial Condition' once the full details are publicly disseminated. (RPRX) — medium confidence, target: 2024-01-09
FAQ
What is the exact name of the registrant as specified in its charter?
The exact name of the registrant as specified in its charter is Royalty Pharma plc, as stated in the filing.
What is the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported in this 8-K filing is January 8, 2024, as indicated in the 'Date of Report' section.
What items of information are being reported in this 8-K filing?
This 8-K filing reports on 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits,' as listed under 'ITEM INFORMATION'.
What is the trading symbol and the exchange on which Royalty Pharma plc's Class A Ordinary Shares are registered?
Royalty Pharma plc's Class A Ordinary Shares have the trading symbol RPRX and are registered on The Nasdaq Stock Market LLC, according to the 'Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934' section.
What is the business address and phone number of Royalty Pharma plc?
The business address of Royalty Pharma plc is 110 East 59th Street, New York, New York 10022, and its telephone number is (212) 883-0200, as provided in the 'BUSINESS ADDRESS' section.
Filing Stats: 531 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2024-01-08 07:18:52
Key Financial Figures
- $0.0001 — red Class A Ordinary Shares, par value $0.0001 per share RPRX The Nasdaq Stock Mar
Filing Documents
- d910834d8k.htm (8-K) — 25KB
- d910834dex991.htm (EX-99.1) — 20KB
- g910834g43d00.jpg (GRAPHIC) — 13KB
- 0001193125-24-003879.txt ( ) — 186KB
- rprx-20240108.xsd (EX-101.SCH) — 3KB
- rprx-20240108_lab.xml (EX-101.LAB) — 17KB
- rprx-20240108_pre.xml (EX-101.PRE) — 11KB
- d910834d8k_htm.xml (XML) — 3KB
02
Item 2.02 Results of Operations and Financial Condition. On January 8, 2024, Royalty Pharma plc issued a press release providing a preliminary update on the year ended December 31, 2023. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information included in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section and shall not be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly stated in such filing.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release issued by Royalty Pharma plc, dated January 8, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirement of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. ROYALTY PHARMA PLC Date: January 8, 2024 By: /s/ Terrance Coyne Terrance Coyne Chief Financial Officer